CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients

CARLSBAD, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) — CarnoSyn® Brands and parent company Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), are pleased to announce a new distribution partnership with B&D Nutritional Ingredients, Inc., a renowned raw material distributor in the dietary supplement industry since 1993. This strategic partnership took effect on October 1st, 2024.

Under the terms of the agreement, B&D will distribute NAI’s newly introduced carnosine booster, TriBsyn™, to the U.S.-based nutritional dietary supplement, functional food, and beverage market segments. Carnosine, which is naturally produced in the body through the synthesizing of beta-alanine and histidine, is a powerful antioxidant that has been shown to provide health benefits for muscle, brain, heart, bone, and overall systemic health. NAI’s new TriBsyn™ product is a patent-pending ingredient that utilizes proprietary technology to increase beta-alanine bioavailability and absorption, while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine. TriBsyn™ provides the opportunity to reach untapped consumers from older adults to vegetarians, vegans, and others looking to boost their carnosine levels.

“This strategic partnership between NAI and B&D is a testament to our longstanding business relationship,” said Mark LeDoux, CEO and Chairman of the Board at NAI. “B&D’s reputation and commitment to their customers is unwavering. This distribution agreement will help drive the awareness and growth of the TriBsyn™ innovation launched in August 2024. We are excited to broaden our distribution efforts with B&D and to share our groundbreaking new ingredient with the industry.”

B&D is a leading distributor specializing in the dietary supplement, functional food and beverage, personal care, pet health, and craft brewery industries. TriBsyn™ represents the latest innovative ingredient added to B&D’s specialty ingredient portfolio for distribution. Their well-stocked warehouse complements just-in-time inventory needs, and a deep understanding of the industry makes B&D a first-class partner.

“B&D is honored to be NAI’s partner to promote TriBsyn™,” stated Bill Van Dyke, B&D President. “TriBsyn™ fits B&Ds’ portfolio and model extremely well by being a clinically supported and unique dietary ingredient. We believe TriBsyn™ will be an excellent ingredient for anti-aging, cognitive function, and support of physical activity.”

About B&D Nutritional Ingredients, Inc.
Founded in 1993 and based in Carlsbad, California, B&D Nutritional Ingredients, Inc. is a national leader in the sales, distribution, and marketing of high-quality dietary ingredients and flavors to the dietary supplement, functional food and beverage, personal care, pet health, and craft brewery industries. B&D has a portfolio of premium ingredients from leading manufacturers supporting a wide array of health benefits that today’s consumers are looking for. B&D is active in several industry organizations representing the dietary supplement, personal care, and pet health industries. Memberships include, Natural Products Association, Consumer Healthcare Products Association, Association of American Feed Control Officials, National Animal Supplement Council. For more information, visit www.bdnutritional.com.

About CarnoSyn® Brands:
CarnoSyn® Brands feature three clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder allows NAI to broaden their product offerings within the dietary supplement category, including medical and other fortified food products. To learn more about SR CarnoSyn® in active nutrition and wellness, visit www.srcarnosyn.com. For more information about the latest innovation, TriBsyn™, visit www.tribsyn.com.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

CONTACT: Contact:
Renee Michaelson
Director of Global Marketing
NAI/CarnoSyn® Brands
(760) 736-7700
info@nai-online.com

Staff

Recent Posts

Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024

Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more…

3 hours ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect…

3 hours ago

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed…

3 hours ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to…

3 hours ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled…

3 hours ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as…

3 hours ago